Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. - Wikidata - wikimedia - TriplyDB

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

http://www.wikidata.org/entity/Q38333986

about

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma Current status and evolution of preclinical drug development models of epithelial ovarian cancer Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer c-FOS suppresses ovarian cancer progression by changing adhesion Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer.POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma.Changes in gene expression and cellular architecture in an ovarian cancer progression model.Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.GPR30 predicts poor survival for ovarian cancer Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data.Epithelial ovarian cancer: An overview.Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma Survival in women with grade 1 serous ovarian carcinoma The transcriptomic profile of ovarian cancer grading The heterogeneity of ovarian cancer.Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.Microenvironment and pathogenesis of epithelial ovarian cancer Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma.The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer.Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.Recent progress in the diagnosis and treatment of ovarian cancer Flaxseed and its components differentially affect estrogen targets in pre-neoplastic hen ovaries Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer Origin of ovarian cancer: molecular profiling The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas.

P2860

Q24650289-2C9E8DBA-2C0D-4F58-AA86-829B83761168 Q27028117-E9E97556-BAA7-416B-8C01-E082842293E3 Q28741689-6A215F24-7538-48AF-8652-8AAE25658DB2 Q30570979-94EB7F1C-157E-46E5-A20E-2BA024681212 Q33387074-37DA3628-8CAB-42DB-89B0-486E20FB3162 Q33511864-184E41FF-88E9-4B8B-BBBC-34FB9D815481 Q33699826-3C32164C-758E-4209-AB67-FDD79CB9D60B Q33747847-1C9CE764-0309-4601-A3BC-EDF7AF79C650 Q33768557-822D0601-0F7C-46E6-96FB-8D3E02BFBB58 Q33842047-7FA44E74-522F-49A4-BA2E-2A8C6D0415D8 Q33867457-3CE91FB0-FFF1-4B7F-8F31-933DD37230D3 Q33874823-ED8E057A-D923-44F1-9FF1-FE5F82936677 Q33962022-A8F98B9C-ABF3-43A9-9BAE-FD0D89806602 Q34066297-8853C134-F1ED-41B8-9736-8DFED6E98024 Q34103978-F238B96C-A081-46D5-9304-33DA5FA66107 Q34162272-F8726B2B-9881-44D3-A352-44E99DCF0A5B Q34185403-699C55CC-1940-498B-891F-B5E9C26CF8DA Q34199368-7D1FC2D7-9E60-486C-B9CE-7E7A6814F755 Q34431079-498AB46B-FA9E-48B2-B126-EEF881E87B8C Q34513043-0DE9AAE8-6E22-4D99-AF0D-3D4E519A26AE Q34708560-990ED2CD-D06C-4B2E-8CFD-2BC289358890 Q34899256-F5C656AD-C8D2-47F9-8678-1589BCCDD1FF Q34967339-D9A72646-7062-4BB1-B4DF-E288429A89D1 Q35032309-169AAECE-E22D-4C52-93A3-E9B339D8D310 Q35062505-26124E95-3276-4EEE-84AB-5A10A6C33CEF Q35140600-BE58754C-EA2E-490D-9758-E66E68C8DEFF Q35419057-F73E9512-AD8F-4B75-951E-25DAD64148F4 Q35857189-DFDEF8A1-F3D3-4808-8131-6F86BCD0DCB3 Q35954415-8F1AF707-F486-4F95-B9AB-B0D0D174CEBA Q36091016-DAD8824A-8917-48D3-9DE9-9095863A5BE1 Q36129967-46173E0D-2C39-485E-A81F-1D5759FB4E76 Q36240028-DD10F24D-FA30-4F39-9BC3-653A1DFEDA0E Q36613726-66807F9D-D3AF-446A-892E-1A4A41F9D649 Q36615861-A7EE9649-4A23-40DE-BD0F-194B41038FA5 Q36622857-D150A7D4-9DF9-473F-91AB-2CB997F020E2 Q36767559-C7521FCC-E51D-462F-975B-1DA8197372B9 Q36768921-F4C807D3-C83A-4E82-8FE9-303E42F4D319 Q36855239-FC248BE2-D920-4073-9839-9646A866A549 Q36965228-FF6A5230-5B9C-49D9-AD6D-CDE01E6D6492 Q37020840-B3A27277-7710-48F5-866E-14C0C24AE858

P2860

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

http://www.wikidata.org/entity/Q38333986

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Molecular and prognostic disti ...... grade and malignant potential.

@en

type

label

Molecular and prognostic disti ...... grade and malignant potential.

@en

prefLabel

Molecular and prognostic disti ...... grade and malignant potential.

@en

P1433

Q38333986-6DB7A692-C139-4D78-9B0C-665EBA8260FB

P1476

Q38333986-C84FD6CC-73EC-4CD8-B7B0-F6FC468B21FE

P2093

Q38333986-04CB6D0D-9EF7-44B0-B040-302EC4579F30

Q38333986-16B92744-77E3-4F61-B045-79A3241F8934

Q38333986-19581023-35E1-41AE-BC59-979A3B640CDC

Q38333986-2B146568-56DF-4F72-A119-9553BEC99D36

Q38333986-38C74C6A-083A-4FF7-AA6A-549E6E5F4A79

Q38333986-3D09ADD2-A3A1-4F8F-BED7-38B2992C2CD1

Q38333986-3E1EC8D0-31AA-48B3-ADB4-0A50597E4CD6

Q38333986-4B0F2086-416A-48CB-9195-B44FE2C9564B

Q38333986-523989C9-E205-493B-B46D-4147F1243896

Q38333986-79259770-4BEC-4BB0-9958-996C6E81D74D

P2860

Q38333986-0A8844CF-8E29-4888-83FF-ED26ABD85B1F

Q38333986-109E3CF8-16B2-4F7D-9A16-8E29721365E9

Q38333986-1CFDC62A-E01B-40C3-A4BF-02887BBA7A8A

Q38333986-1D42FD46-45FA-4474-AC18-D8EFB4284CE0

Q38333986-209D93D3-11B1-40DE-9619-15AB914E9F4F

Q38333986-21E88443-42ED-4A01-B27B-3B6C91B68D5E

Q38333986-46D27616-E6C5-48AE-95BE-77FA30857414

Q38333986-4F53EB57-CAC7-4DDD-BB5D-A0245461C19F

Q38333986-5BCF88CC-DCAC-4900-BA90-9BB43976F01D

Q38333986-6583AA2D-483F-4BCD-9374-6BACA764D33D

P2888

Q38333986-2AE8636E-264A-47B4-8A3B-9266578333D3

P304

Q38333986-E24C00E4-EC6B-472B-A0A1-AE4723BFA68B

P31

Q38333986-5288FEEF-E51D-4EFB-96C1-F99C415F124A

P356

Q38333986-84CBAB33-05A6-4D19-9651-CE769B56DAD6

P407

Q38333986-A210E806-15C9-4062-B2E2-C0037E9F78A8

P433

Q38333986-E2A04310-2C70-41A7-9318-D32528DEFABE

P478

Q38333986-B5E51FF6-6378-4F2C-B443-8E3EFF707A8F

P50

Q38333986-B2D71F5F-C1B1-4CF5-A3D5-C7BB4089376D

Q38333986-D9A3ED1D-68EE-4BAF-A790-C2288D7F5E2A

Q38333986-F534E31E-3643-494E-BC70-29B981357C5F

Q38333986-FCD91FEF-8D71-4DA4-8EE3-CA0C313BEDD2

P577

Q38333986-3C49E35D-1B12-4D63-944E-A783DD53F9B4

P6179

Q38333986-5A3A12D3-16FA-408C-97D7-8858939C93F6

P698

Q38333986-6F3AA5BC-2175-43CF-841D-6A6980BA9C3E

P356

P1433

P1476

Molecular and prognostic disti ...... grade and malignant potential.

@en

P2093

Anja Jacobsen

http://www.w3.org/2001/XMLSchema#string

Dirk Bauerschlag

http://www.w3.org/2001/XMLSchema#string

Felix Hilpert

http://www.w3.org/2001/XMLSchema#string

Garret M Hampton

http://www.w3.org/2001/XMLSchema#string

John C Reed

http://www.w3.org/2001/XMLSchema#string

Jutta Luttges

http://www.w3.org/2001/XMLSchema#string

Lisa M Sapinoso

http://www.w3.org/2001/XMLSchema#string

Maryla Krajewski

http://www.w3.org/2001/XMLSchema#string

Marzenna Orlowska-Volk

http://www.w3.org/2001/XMLSchema#string

Petre Dimitrov

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

GADD34 induces p53 phosphorylation and p21/WAF1 transcription

The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells

Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway

Significance analysis of microarrays applied to the ionizing radiation response

Cluster analysis and display of genome-wide expression patterns

Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen

Expression monitoring by hybridization to high-density oligonucleotide arrays

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

Gadd34 functional domains involved in growth suppression and apoptosis

P2888

P304

1053-1065

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1208298

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Ivo Meinhold-Heerlein

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1040092111

http://www.w3.org/2001/XMLSchema#string

P698

15558012

http://www.w3.org/2001/XMLSchema#string